SCHEDULE 13G/A: Highbridge Capital Management Discloses Passive 3.2% Stake in OnKure Therapeutics
Beneficial Ownership Report
Highbridge Capital Management, LLC has filed an amended Schedule 13G, reporting a passive beneficial ownership of 3.2% of OnKure Therapeutics, Inc.'s Class A Common Stock as of December 31, 2024.
Summary
- Highbridge Capital Management, LLC reported beneficial ownership of 399,743 shares of OnKure Therapeutics, Inc.'s Class A Common Stock.
- This stake represents 3.2% of the total outstanding Class A Common Stock.
- The percentage is calculated based on 12,652,890 shares of Class A Common Stock outstanding as of November 4, 2024, as reported in the Issuer's Form 10-Q.
- Highbridge Capital Management, LLC, acting as an investment adviser, holds these shares for various funds and accounts (Highbridge Funds).
- The filing certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of OnKure Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of a passive beneficial ownership stake, providing no new operational or financial information about the issuer that would significantly alter sentiment.
Positives
- A notable investment management firm, Highbridge Capital Management, holds a significant, albeit passive, stake in OnKure Therapeutics, which could be viewed as a vote of confidence in the company.
Negatives
- No explicit negative information regarding OnKure Therapeutics, Inc. is provided in this beneficial ownership filing.
Risks
- This Schedule 13G filing does not contain specific risk factors related to OnKure Therapeutics, Inc.'s operations or financial health.
Future Outlook
This Schedule 13G filing does not provide any forward-looking statements or guidance regarding OnKure Therapeutics, Inc.'s future performance or Highbridge Capital Management's investment strategy beyond the passive nature of the current holding.
Industry Context
This filing is a routine disclosure of a passive investment by a hedge fund in a biotechnology or pharmaceutical company. It does not provide specific insights into broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake in the company, confirming a notable holder without indicating an intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 2024-11-04 | Date as of which 12,652,890 shares of Class A Common Stock were reported outstanding in the Issuer's Form 10-Q. |
| 2024-11-07 | Date the Issuer's Quarterly Report on Form 10-Q for the period ended September 30, 2024, was filed with the SEC. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-02-07 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
OnKure Therapeutics, Highbridge Capital Management, Schedule 13G, beneficial ownership, Class A Common Stock, investment adviser, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.